Cart
sales@molnova.com
Home - Products - Angiogenesis - CDK - ON-013100

ON-013100

CAS No. 865783-95-5

ON-013100( —— )

Catalog No. M26776 CAS No. 865783-95-5

ON-013100 is an antineoplastic drug. ON-013100 also acts as a mitotic inhibitor that could inhibit Cyclin D1 expression.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 55 Get Quote
5MG 65 Get Quote
10MG 102 Get Quote
25MG 181 Get Quote
50MG 276 Get Quote
100MG 417 Get Quote
200MG 589 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    ON-013100
  • Note
    Research use only, not for human use.
  • Brief Description
    ON-013100 is an antineoplastic drug. ON-013100 also acts as a mitotic inhibitor that could inhibit Cyclin D1 expression.
  • Description
    ON-013100 is an antineoplastic drug. ON-013100 also acts as a mitotic inhibitor that could inhibit Cyclin D1 expression.(In Vitro):ON 013100 inhibits the proliferation of MCL (JEKO-1 and MINO), breast (MCF7 and MDA-MB-231), gastric (AGS), and esophageal (OE19, OE33, and FLO-1) cancer cell lines at a nanomolar concentration (ON 013100 GI50=6.7-11.2 nM). ON013100 significantly alters the cell cycle profile, dramatically increasing the number of cells in the G2/M phase. Treatment of the cells with even 0.1 μM of ON013100 results in an arrest of the G2/M phase of the cell cycle. ON-013100 induces apoptosis and has activity against most human cancer cell lines in vitro.
  • In Vitro
    ON-013100 induces apoptosis, and has activity against most human cancer cell lines in vitro. ON013100 significantly alters the cell cycle profile, dramatically increasing the number of cells in G2/M phase. Treatment of the cells with even 0.1 μM of ON013100 results in an arrest of the G2/M phase of the cell cycle. ON 013100 inhibits the proliferation of MCL (JEKO-1 and MINO), breast (MCF7 and MDA-MB-231), gastric (AGS), and esophageal (OE19, OE33, and FLO-1) cancer cell lines at a nanomolar concentration (ON 013100 GI50=6.7-11.2 nM) .
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    CDK
  • Recptor
    Sweet taste receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    865783-95-5
  • Formula Weight
    394.44
  • Molecular Formula
    C19H22O7S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 25 mg/mL (63.38 mM)
  • SMILES
    COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(O)c2)c(OC)c1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Hamano K, et al. Lactisole inhibits the glucose-sensing receptor T1R3 expressed in mouse pancreatic β-cells. J Endocrinol. 2015 Jul;226(1):57-66.
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • CDK12-IN-2

    CDK12-IN-2 is an effective and selective inhibitor of CDK12 with an IC50 of 52 nM, >100 μM, >10 μM and 16 μM for CDK12, CDK2, CDK7, and CDK9. CDK12-IN-2 can be used in studies about the function of CDK12.

  • Purvalanol B

    A potent, cell-permeable, selective inhibitor of CDK with IC50s of 6, 6, 9, and 6 nM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E, and cdk5-p35 respectively.

  • THZ-1

    A potent, selective, covalent CDK7 inhibitor with IC50 of 3.2 nM; also weakly inhibits CDK12 with IC50 of 250 nM; displays broad-based activity a subset of cancer cell lines with IC50s of <200 nM.

Sign In Join Free